DRF-1042

200619-13-2

408.40

DMSO : 50 mg/mL (122.43 mM; Need ultrasonic)

Cell Cycle/DNA Damage; Antibody-drug Conjugate/ADC Related

DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype^[1][2]. IC50 & Target: DNA topoisomerase I^[1] In Vitro: DRF-1042 demonstrates superior lactone stability and good in vitro anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype^[2]. In Vivo: In clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies^[2].